Infusion of CD133 þ selected HSC not preceded by any immunosuppressive treatment has recently been reported in this Journal by Lang et al, 1 as an effective therapy for isolated thrombocytopenia post allogeneic bone marrow transplantation in a patient affected by Wiskott-Aldrich Syndrome. In this report the authors wonder whether other methods of HSC selection not based on CD133 þ could have been equally effective.
We here report a case of graft failure occurring after a T-cell replete allogeneic HSC transplantation that was successfully treated using an infusion of CD34 þ immunoselected HSC without any prior immunosuppression.
In our Institution, a 30-year-old female patient underwent an allogeneic bone marrow transplantation from an HLA-identical sibling donor because of an AML in first remission. Leukaemia had been treated with two cycles of chemotherapy employing VP16, ARA-C and DNR, and a subsequent consolidation cycle of high dose ARA-C.
Transplantation was performed on 22 October 2001, using BU-CY conditioning, graft-versus-host disease (GvHD) prophylaxis was CSA plus methotrexate. The donor was the patient's 27-year-old sister of the same blood group, both donor and recipient were CMV seropositive. A bone marrow harvest was infused without any manipulation, the cellular content of inoculum per recipient body weight was: TNC: 5.8 Â 10 At day þ 45 CMV reactivation was detected by CMV antigenemia in PB and the patient was started on Foscavir for 21 days.
The patient never reached PLT count 420 Â 10 9 /l and a bone marrow biopsy carried out on day þ 59 showed a severe hypocellular marrow (cellularity 10%) in the absence of blast cells. Haemorrhagic cystitis was present from days þ 59 to þ 100. Patient was eventually discharged on day þ 100 with the following blood count: Hb 8.5 g/dl, PLT 11.0 Â 10 9 /l, N 0.7 Â 10 9 /l. CSA was stopped on day þ 190. The subsequent course during the 2 years and 7 months after transplantation was characterized by a persistent thrombocytopenia with PLT count varying from 5.0 Â 10 9 to 20.0 Â 10 9 /l, by anaemia with a blood transfusion requirement of 1-2 U every month and no response to EPO treatment, and by mild neutropenia with N count varying from 0.7 to 1.2 Â 10 9 /l. Serial bone marrow biopsies showed persistence of severe hypocellularity but no AML blast cells. Given the blood transfusion requirement, a second transplant using a boost of HSC was planned. Since chimerism showed that in PB 98% of WBC were of the donor type, a graft rejection was considered unlikely and we therefore decided not to administer any immunosuppression before the second graft infusion. In order to decrease the risk of GvHD we performed a T-cell depletion of HSC graft by means of CD34 þ cell immunoselection. The donor was mobilized with G-CSF at dosage of 10 mg/ kg/day/s.c. and underwent two aphaeresis sessions during which a total CD34 þ of 4.4 Â 10 6 /kg were collected. CD34 þ cell selection was performed using an ISOLEX 300i (BAXTER). At 2 years and 7 months after the first transplant, the patient received, without any prior immunosuppressive treatment, an HPC boost containing 3.5 Â 10 6 /kg CD34 þ cells and 4.6 Â 10 4 /kg CD3 þ lymphocytes. Haematological blood count correction was rapid and at day þ 13 after the CD34 þ selected boost PLT were 52 Â 10 9 /l, N were 2.9 Â 10 9 /l and HB 9.4 g/dl. At day þ 100 PB counts were: PLT 104 Â 10 9 /l, N 3.9 Â 10 9 /l and Hb 12.5 g/dl.
Graft dysfunction may be the result of microenvironment abnormalities pre-existing the transplant or of toxic effects toward HSC from viral infections or drugs. Graft dysfunction may also be due to an immunological reaction: during GvHD an immunologic mediated damage toward bone marrow stroma may occur, 2 recipient T lymphocytes resisting conditioning regimen may also explicate a cytotoxic action toward donor HSC. 3 Such 'host-versusgraft' reaction can be antagonized by infusion of donor T-lymphocytes which thus can favour engraftment, 4 while T-depletion of the graft is associated with higher risk of graft rejection. 5 For this reason, the treatment of graft failure after an allogeneic bone marrow transplantation is usually based on administration to recipient of an eradicating and immunosuppressive scheme 6 or on administration of an immunosuppressive only therapy. 7 These treatments are usually followed by infusion of a boost of donor T-cell repleted HSC. A second transplant, however, carries the risks of immunosuppression, toxicity and acute GvHD. 5 An HSC boost not preceded by immunosuppression can avoid some of these risks and the value of this therapeutic option is considered one of the 'still open' questions of graft failure treatment. 8 A boost of T-cell depleted HPC not preceded by any immunosuppression could avoid the risk of GvHD, but the probability of engraftment of such inocolum is unknown.
Our case is the first case reported in literature on the employment of a CD34 þ selected HSC boost without any prior conditioning to treat a graft failure following a T-cell repleted bone marrow transplantation. Two cases of graft failure after T-cell depleted allogeneic bone marrow transplantation successfully treated with a CD34 þ selected boost have been already reported by Mohty et al. 9 Graft failure in these cases followed a T-cell depleted transplant using a graft with a low number of CD34 þ cells, in both cases less than 1.0 Â 10 successfully treated by Mohty et al, chimerism study before boost infusions showed that lymphoid cells in PB were of donor origin. This makes an immunological basis for the graft failure unlikely, since in this event a predominance of recipient T lymphocytes would be expected. 10 In conclusion, our case report underlines that a CD34 þ selected boost without any prior immunosuppressive treatment may be a risk free and effective treatment of graft failure after allogeneic bone marrow transplantation. This treatment should be considered when mixed chimerism study does not support an immune basis for the graft failure. Milone et al report a case of graft failure occurring after a T-cell replete allogeneic HSC transplantation that was successfully treated using an infusion of immunoselected HSC without any prior immunosuppression. The authors refer to a similar case from our institution (a 12-year-old boy with sustained low platelet counts after transplantation of unmanipulated bone marrow from his non-identical father, in whom a stem cell boost of purified CD133 þ selected peripheral progenitors improved megakaryopoiesis markedly 1 ) and raise the question whether CD34 þ selected HSC may be equally effective.
G Milone
We absolutely agree with the authors: CD133 þ selected as well as CD34 þ selected HSC have also been used in our institution to improve and to stabilize hematopoiesis after T-cell depleted or T-cell reduced transplantation from alternative donors. Boosts were given between 19 and 498 days and no severe GvHD was induced. Thus, patients in whom transplant tolerance already has been achieved may benefit from boosts with positive (CD34 þ or CD133 þ ) selected stem cells also in our experience. Ongoing studies need to clarify if CD133 þ selected cells will be more effective than CD34 þ selected progenitors, especially in terms of platelet recovery, or not.
